DNA Content/Cell Cycle Analysis, Breast (Paraffin) (Inactive as of 05/19/14 Refer to 0095155)
Ordering Recommendation
Quantitative Flow Cytometry
Sun, Tue
3-9 days
New York DOH Approval Status
Specimens from New York clients will be sent out to a New York DOH approved laboratory, if possible.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Breast tumor tissue. 
Specimen Preparation
Paraffin embed tissue block enriched with breast tumor. If no normal tissue is included in the block, supply a control tissue block to be processed in parallel. 
Storage/Transport Temperature
Unacceptable Conditions
No tumor tissue remaining on block. Specimens fixed in Bouin's solution (picric acid), mercuric chloride containing fixatives (e.g., B5, Zenker's solution), or ethanol-based fixatives containing ethylene glycol, acetic acid, or zinc chloride. Decalcified specimens. 
Include H&E stained slide and surgical pathology report. 
Paraffin block: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable 
Reference Interval
Report components include: DNA content, S-phase interpretation, and a copy of the histogram.
Interpretive Data
In large retrospective studies, aneuploidy was identified in about 50 percent of breast cancers. Out of 34 studies on DNA content in primary breast cancer, 15 found aneuploidy an adverse prognostic factor on multivariate analysis, 6 found ploidy status predictive on univariant analysis only, and 11 found no prognostic significance. Thus, the clinical use of DNA content in breast cancer is controversial. Aneuploidy and high S-phase are associated with large tumor size, node involvement, high histological grade and hormone receptor negativity. Some reports suggest that low S-phase correlates with a good prognosis. [Am J Clin Pathol 2003, 120 (Suppl 1):S72-S84; Clin Cancer Res 2001, 7:909-17].

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

A thin section of each tissue submitted is stained with H & E to verify the presence of tumor. The DNA content of each tumor is classified, in order of worsening prognosis, as diploid, near diploid, tetraploid, aneuploid, or hypertetraploid. The DNA index is the ratio of tumor G0-G1 cells to normal G0-G1 cells.

The tumor-specific S-phase is used when possible. An average histogram S-phase is used for diploid and some aneuploid tumors where the tumor and host S-phases cannot be separated. An average histogram S-phase is also used when the percentage of aneuploid cells in the histogram is low (less than 25%). The S-phase interpretation is based on comparison to over 5,000 breast tumors, controlled for histogram type (diploid, near-diploid, aneuploid) and sample type (fresh/frozen, paraffin). The appropriate population is divided into thirds and compared to the sample S-phase for an interpretation of low, moderate, or high S-phase.
CPT Code(s)
Component Test Code*Component Chart NameLOINC
0095731DNA Content, Breast30911-2
0095732DNA Content, Breast, S-Phase Interp.41294-0
2008900DNA Index, Breast
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Breast Cancer aneuploidy
  • DNA Ploidy and S-Phase